Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tree-based exploratory identification of predictive biomarkers in non-randomized data.

BMC medical research methodology·2026
Same author

Letermovir does not affect long-term polyclonal immune reconstitution after allogeneic hematopoietic stem cell transplantation with ATG-based GvHD prophylaxis.

Frontiers in immunology·2026
Same author

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

MRI Quality and Reader Experience in Organized Prostate Cancer Screening: Insights from the PROBASE Trial.

European urology oncology·2026
Same author

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Perioperative factors influencing immediate and long-term continence after robot-assisted radical prostatectomy.

BJUI compass·2026

Related Experiment Video

Updated: Feb 23, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

746

Relapsed/refractory acute myeloid leukemia: any progress?

Richard F Schlenk1, Carsten Müller-Tidow, Axel Benner

  • 1aNCT-Trial Center, German Cancer Research Center bDepartment of Hematology and Oncology, University of Heidelberg cDivision of Biostatistics, German Cancer Research Center dInstitute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.

Current Opinion in Oncology
|September 1, 2017
PubMed
Summary

New prognostic markers like FLT3-ITD and IDH1 mutations aid in relapsed/refractory acute myeloid leukemia (r/r-AML) treatment. Allogeneic stem cell transplant timing and novel therapies are key for improving outcomes in r/r-AML.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.7K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

839

Related Experiment Videos

Last Updated: Feb 23, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

746
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.7K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

839

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Relapsed/refractory acute myeloid leukemia (r/r-AML) presents significant treatment challenges.
  • Identifying reliable prognostic and predictive factors is crucial for optimizing patient management.

Purpose of the Study:

  • To review prognostic/predictive factors in r/r-AML.
  • To discuss standard and novel therapeutic strategies.
  • To address statistical considerations for future clinical trials in r/r-AML.

Main Methods:

  • Literature review focusing on prognostic markers, treatment approaches, and clinical trial design.
  • Analysis of recent findings in r/r-AML research.
  • Evaluation of statistical methodologies for clinical trials.

Main Results:

  • FLT3-ITD, mutated IDH1, and biallelic CEBPA mutations identified as key prognostic markers in r/r-AML.
  • Intensive chemotherapy with gemtuzumab ozogamicin shows efficacy as salvage therapy.
  • Allogeneic hematopoietic stem cell transplantation (allo-HCT) timing should align with response probability to salvage therapy.

Conclusions:

  • FLT3-ITD, mutated IDH1, and biallelic CEBPA mutations are confirmed prognostic markers.
  • Allo-HCT timing is critical and should be guided by salvage therapy response.
  • Novel therapeutic approaches are under development, with matching designs potentially enhancing external validity of trial results.